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Purpose: The purpose of this study is to investigate the distribution and antimicrobial 
  susceptibility of pathogenic bacteria in inpatients with pulmonary infection in the neurological 
intensive care unit (NICU).
Methods: A total of 947 sputum specimens of 428 inpatients from May 2007 to May 2008 in 
the NICU were enrolled in the study, and bacterial identification and antibiotic susceptibility 
tests were analyzed using a VITEK 2 system.
Results: A total of 400 positive bacterial strains were separated from 947 sputum specimens, with 
Gram-negative bacteria accounting for 69.0% of the total strains collected. The most common 
strain of Gram-negative bacteria was Klebsiella pneumoniae (20.5%). Gram-positive bacteria 
accounted for 10.0% of the total strains, with the most common strain being Staphylococcus 
aureus (2.5%). Fungal species accounted for 21.0% of the total strains, and the most common 
strain collected was Candida albicans (12.25%). Imipenem was the most effective antibiotic 
against Gram-positive and Gram-negative bacteria. The drug resistance rate of Gram-positive 
bacteria to penicillin G was 100%, and the Gram-positive bacteria were 100% sensitive to 
teicoplanin, vancomycin, and linezolid.
Conclusions: Gram-negative bacterial infections account for the majority of pulmonary 
infections in the NICU, with fungal infections being the second most common infection type 
observed. In addition, fungal infections seem to be related to mortality in the NICU.
Keywords: nosocomial infection, pulmonary infection, drug resistance, neurological intensive 
care unit
Introduction
The neurological intensive care unit (NICU) is the main place where neurocritical 
patients are admitted. The chance of infection in the NICU is higher than in the 
general wards because operations such as endotracheal intubation, incision, sputum 
suction, and catheterization are performed. Pulmonary infection is a major form of 
nosocomial infection, and it is associated with increased length of stay and   mortality 
in intensive care units (ICUs).1,2 With the new types of antibiotics widely used in the 
clinic, the emergence of pathogenic bacteria have increased, and multidrug   resistant 
and high drug-resistant strains are having a negative impact on the prognosis of 
inpatients.3 To understand the distribution and changes in trends of pathogenic 
bacteria in NICU, we carried out bacterial culture and antimicrobial susceptibility 
tests on sputum   specimens of inpatients from May 2007 to May 2008 in the NICU 
of our hospital.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Methods
This research was approved as a clinical prospective 
  observational cohort study by the ethics committee of the 
First Affiliated Hospital of Chongqing Medical University 
in Chongqing, China. Informed consents were obtained from 
all subjects prior to the study. Our NICU comprises 18 beds 
with an average of 1500 admissions/year.
A total of 947 sputum specimens were collected from 
428 patients with pulmonary infection after admission 
in our NICU from May 1, 2007 to May 31, 2008. All 
patients were   admitted to the NICU for more than 48 h. 
The   standardized   criteria for respiratory infections include 
fever, cough, increased leukocyte count (.10 × 109/L), 
increased   neutrophil percentages (.80%), and harsh 
breath sounds with dry and medium rales or wheezy 
phlegm. Signs of   pulmonary infection were observed by 
chest X-ray. Routine sputum specimens were submitted 
for tests, and   bronchoalveolar lavage fluid was collected if 
the patient underwent tracheal   intubation or tracheotomy. 
Bacterial   identification and   antibiotic susceptibility tests 
were performed on all   specimens with a VITEK 2 system 
(bioMérieux, Marcy l’Etoile, France) in the Department of 
  Microbiology in our hospital,4,5 and the following standard 
quality control strains were obtained from the National 
Committee for   Clinical Laboratory Standards of China: 
Pseudomonas aeruginosa ATCC 27853, Staphylococcus 
aureus ATCC 25923, and Escherichia coli ATCC 25922.
The µ test, description of measurement, and   enumeration of 
data were performed using SPSS 11.0 (SPSS Inc,   Chicago, IL). 
The central tendency was described by arithmetic mean, and 
the relative number was demonstrated with the ratio and 
  frequency. Statistical significance was defined as P , 0.05.
Results
A total of 428 neurocritical patients were enrolled in this 
study: 225 were females and 203 were males. The demo-
graphics, underlying diseases, and outcomes of these patients 
are shown in Table 1. The median age was 61.2 years, and 
the median length of the hospital stay was 7.4 days. Thirty 
patients (7%) died during the period of admission.
A total of 400 pathogenic strains were detected in 947 
  sputum specimens with a 42.2% positive rate. Of these strains, 
276 were Gram-negative bacteria, accounting for 69.0% of total 
species, and included Klebsiella   pneumonia, P . aeruginosa, 
and Acinetobacter baumannii. Among the strains collected, 
forty were Gram-positive bacteria,   accounting for 10.0%, 
and included S. aureus,   Staphylococcus epidermidis, and 
Hemolytic staphylococcus. A total of 84 strains were fungi, 
including Candida albicans (Table 2).
Imipenem was the most effective antibiotic for the   treatment 
of Gram-positive and Gram-negative bacteria. The drug 
resistance rate of Gram-positive bacteria was 100% to peni-
cillin G and above 80% to erythromycin, azithromycin, and 
  clarithromycin. Gram-positive bacteria were 100%   sensitive 
to teicoplanin, vancomycin, and linezolid. The   antibiotic 
Table 1 The demographics, underlying diseases, and outcomes 
of inpatients
Variable Values
Median age 61.2 years (16–89)
gender
  Male 225 (52.6%)
  Female 203 (47.4%)
Admission diagnosis
  Cerebral infarction 140 (32.7%)
  intracerebral hemorrhage 69 (16.1%)
  subarachnoid hemorrhage 38 (8.9%)
  encephalitis 48 (11.2%)
  Tuberculous meningitis 15 (3.5%)
  Multiple sclerosis 27 (6.3%)
  guillain–Barre syndrome 20 (4.7%)
  Acute myelitis 12 (2.8%)
  status epilepticus 35 (8.2%)
  encephalopathy 24 (5.6%)
Median length of niCU stay 7.4 days (2–30)
Outcome
  Discharged 398 (93.0%)
  Mortality 30 (7.0%)
Table  2  The  distribution  and  ratio  of  pulmonary  infection 
pathogens in niCU
Bacterium Numbers (strain) Percentage
gram-negative bacteria 276 69.0
  Klebsiella pneumoniae 82 20.5
  Pseudomonas aeruginosa 62 15.5
  Acinetobacter baumannii 48 12.0
  Pseudomonas maltophilia 14 3.5
  Enterobacter cloacae 10 2.5
  Flu hemophilic bacteria 6 1.5
  Acinetobacter junii 4 1.0
  Enterobacter aerogenes 4 1.0
  Others 46 11.5
gram-positive bacteria 40 10.0
  Staphylococcus aureus 10 2.5
  Staphylococcus epidermidis 10 2.5
  Hemolytic staphylococcus 7 1.75
  Others 13 3.25
Fungus 84 21.0
  Candida albicans 49 12.25
  Candida tropicalis 15 3.75
  Others 20 5.0Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Resistance rates of common gram-negative bacilli to 
antibiotics (%)
Antibiotics Klebsiella  
pneumoniae  
(N = 82)
Pseudomonas  
aeruginosa  
(N = 62)
Acinetobacter   
baumannii  
(N = 48)
Ampicillin 100 100 100
Co-trimoxazole 100 100 100
Amoxicillin 100 – 100
Cephalothin 100 – 100
Cefotaxime 100 – 100
netilmicin 100 – 100
Cefuroxime 100 – 100
Ticarcillin 100 95.16 100
Piperacillin 100 61.29 100
Cefazolin 90 100 100
Ampicillin/ 
sulbactam
90 100 87.50
gentamicin 82.72 75.38 72.92
nitrofurantoin 80 100 100
Ceftriaxone 76.25 100 100
Cefepime 72.84 55.38 55.32
Trimethoprim/ 
sulfamethoxazole
72.5 100 86.96
Aztreonam 72.5 67.21 78.26
Tetracycline 72 100 100
Ceftazidime 71.6 66.15 77.08
Ceftizoxime 62 96.55 76.67
Ticarcillin/ 
clavulanic acid
60.78 95.08 68.97
Tobramycin 60.49 73.85 60.42
Amikacin 56.25 37.70 34.78
Ciprofloxacin 54.34 76.92 75
Levofloxacin 51.25 59.02 17.02
Piperacillin/
tazobactam
16.25 28.13 20
Cefotetan 10 100 100
ertapenem 10 – –
imipenem 1.23 35.38 2.08
Cefoxitin 0 – 100
Meropenem 0 43.10 0
resistance rates of common Gram-negative bacilli and 
Gram-  positive cocci are shown in Tables 3 and 4.
A total of 36 strains were detected from 30 deceased inpa-
tients; 14 of these were fungal strains, with a 38.9% positive 
rate. A total of 364 strains were detected in 398 discharged 
inpatients, with 70 fungal strains with a 19.2% positive rate. 
When the positive rates of fungal infection in the mortality 
and discharged groups were compared, a statistical difference 
was found (P , 0.05).
Discussion
Patients in the NICU are always dangerously ill, and most of 
them display limited activity and consciousness disturbances. 
Pulmonary infection is the most common complication for 
these patients. In this study, we investigated the distribu-
tion and antimicrobial susceptibility of pathogenic bacteria 
associated with pulmonary infection in inpatients in NICU. 
Pathogenic bacteria were defined when bacterial identifi-
cation determined that the same pathogenic bacteria two 
successive or predominant bacteria growth was observed 
3 times. Thus, only 400 strains of pathogens were detected 
with a 42.2% positive rate. Finally, we analyzed the positive 
strains and found that a low positive rate did not affect the 
level of bacteria distribution or the resistance rate.
In our NICU, the most common pathogens associated 
with pulmonary infection were Gram-negative bacilli, 
accounting for 69.0%; this finding is in accordance with 
reports that Gram-negative bacteria are the most com-
mon pathogens associated with nosocomial infections.6 
In the general population, the majority of pulmonary 
infections are caused by S. pneumoniae, but in our NICU, 
the three most common pathogens associated with pul-
monary   infection were K. pneumonia, P . aeruginosa, 
and A. b  aumannii. Our data show that K. pneumonia, 
P . aeruginosa, and A.   baumannii have high resistance 
rates to penicillins, with the exception of piperacillin/
tazobactam. Studies have shown that   drug-resistant mecha-
nism for penicillins may be mainly due to the fact that the 
bacterium produces β-lactamase, which breaks open the 
β-lactam ring of the antibiotic, rendering the penicillins 
ineffective.7 K. pneumonia and A. baumannii are relatively 
efficient to carbapenems, and resistance rates for imipenem 
are 1.23% and 2.08%, respectively; both are efficient to 
meropenem. Carbapenem antibiotics gain access to the 
cytoplasm and combine with penicillin-binding protein 
(PBP) through the proteins with permeability on bacterial 
outer membrane, by interfering with cell wall synthesis 
and thus sterilize, because the majority of β-lactamase 
have with a high degree of stability, so the treatment can 
achieve a   better efficacy.8 Clinicians can use carbapenem 
antibiotics as empiric antibiotics to treat infections caused 
by   K.   pneumonia and A. baumannii.9 After obtaining drug 
susceptibility data, we can rationally adjust the concentra-
tions of effective antibiotics.
P . aeruginosa showed a resistance rate of more than 
30% to imipenem and meropenem. This rate is higher than 
that reported in literature.6 Piperacillin/tazobactam as com-
bination therapy against P . aeruginosa showed the lowest 
resistance rate.10 Prevalence of P . aeruginosa has gradually 
increased and has become one of the major pathogenic Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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bacteria in the ICU.11,12 Some researchers have found that 
carbapenem-resistant P . aeruginosa is a risk factor for patient 
mortality.13 The resistance mechanisms include the produc-
tion of β-lactamses, efflux pumps, and target-site or outer 
membrane modifications.14
Gram-positive bacteria were the least prevalent 
group of pathogens found in the NICU and include 
S. aureus, S. epidermidis, and Hemolytic staphylococcus. 
These strains are sensitive to teicoplanin and vancomycin, 
show high sensitivity to rifampicin, and are resistant to 
penicillin antibiotics. These findings are in accordance with 
the literature.15,16
In our study, we found that fungus was the second 
largest group of pathogens associated with pulmonary 
infection in our NICU. This proportion (21%) is higher 
than that reported in literature.17 C. albicans is the most 
common fungal pathogen and is effective to fluconazole. 
One study showed that invasive fungal infections have 
become a major cause of morbidity and mortality in ICU, 
and invasive candidiasis accounts for up to 15%–30% of 
all nosocomial infections in critically ill patients.18 We also 
found that   fungal infection seemed to be related to mortality 
in our NICU. There are some reasons to explain the high 
proportions of fungal infections in the NICU. First, using 
broad-spectrum   antibiotics might inhibit the normal flora 
in the body and cause malignant growth of fungi. Second, 
patients in the NICU are severely ill with low immunity and 
high vulnerability to fungal infection. Finally, some medica-
tions commonly used to treat nervous system diseases, such 
as glucocorticoids, could cause disorder to the balance of 
the microecology in the body, causing dysbacteriosis and 
inducing increased fungal infection.
Currently, antibacterial resistance has become a serious 
problem in the NICU. This study was carried out at a single 
center, and our goal was to understand the changes in the 
distribution of bacterial strains and bacterial resistance in 
the NICU. We found that Gram-negative bacteria are still 
the most common pathogens associated with nosocomial 
pulmonary infections, whereas the percentages of fungal 
infection are higher than those reported in the literature and 
more related to mortality in our NICU. Bacteria are highly 
resistant to commonly used antibiotics, so bacterial culture 
and drug susceptibility tests are necessary for rationalizing 
the use of antibiotics and for correctly taking standard 
  preventive measures and care.
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Table 4 Resistance rates of common gram-positive cocci to antibiotics (%)
Antibiotics Staphylococcus aureus 
(N = 10)
Staphylococcus epidermidis 
(N = 10)
Hemolytic staphylococcus 
(N = 7)
Penicillin g 100 100 100
erythromycin 100 80 100
Azithromycin 100 80 100
Clarithromycin 100 80 100
Ciprofloxacin 100 70 100
Tetracycline 100 20 14.29
Amoxicillin 90 90 100
Ampicillin/sulbactam 90 90 100
Cefaclor 90 90 100
Oxacillin 90 90 85.71
gentamicin 90 50 100
imipenem 88.89 90 100
Ceftriaxone 88.89 90 100
Cefuroxime 88.89 90 100
Cefotaxime 88.89 90 100
Rifampicin 70 40 14.29
Fosfomycin 44.44 10 100
Trimethoprim/sulfamethoxazole 42.86 90 60
Moxifloxacin 33.33 10 0
Fusidate 22.22 10 0
Dalfopristin 0 0 0
Linezolid 0 0 0
Teicoplanin 0 0 0
Vancomycin 0 0 0Therapeutics and Clinical Risk Management
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